KA/EN
Register
Medicines reference
Search
Search
Product

Ciprinol

Favourites

Ciprofloxacin · Krka

4 forms: coated tablet, solution. In force in Georgia: 4 of 4 (human register).

Forms and doses4 of 4 in force in Georgia

Form Dose Frequency Georgia
2 mg/ml, Solution No label dose in the reference yet - Georgia Yes, human
In force until 03 Aug 2027
Human (Ministry of Health, RAMA)
In the register: ციპრინოლი 2 მგ/მლ, საინფუზიო ხსნარი, 100 მლ
№ რ-036072
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Ciprinol 2 mg/ml, Solution

solution for infusion, 100 ml, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Specialist-directed intravenous ciprofloxacin for a confirmed serious susceptible bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy
6.3/10
Situational / acceptable
vetman assessment

Ciprinol

2 mg/ml, solution for infusion, 100 ml, human medicine
Assessed clinical scopeDog · Specialist-directed intravenous ciprofloxacin for a confirmed serious susceptible bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy · Intravenous
Care settingHospital treatment after diagnostic sampling, with controlled infusion, exact weight and renal assessment, interaction review, monitoring and culture-guided de-escalation.
vetman score 6.3/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-036072 · Verified on 16 Oct 2026 Off-label use

A situational hospital reserve rather than a routine antimicrobial. IV delivery gives more predictable exposure than ciprofloxacin tablets and the ready solution is workable, but stewardship restrictions, absent veterinary breakpoints and limited clinical-outcome evidence keep licensed, better-characterised veterinary alternatives preferred.

Regulatory and scientific credibility7.5/10

This exact human Ciprinol presentation has sourced active registrations in Georgia and EU/EEA and current exact product information, with no exact GB or US registration in the checked registers. Animal use is off-label and licensed veterinary fluoroquinolones are available.

Clinical efficacy5.5/10

Intravenous delivery avoids the low and highly variable canine tablet absorption, and two small canine PK studies describe wide, linear disposition at 2.5-10 mg/kg and similar kinetics during induced fever. However, there is no robust veterinary clinical-outcome programme or approved ciprofloxacin breakpoint, while current guidelines reserve fluoroquinolones and favour licensed veterinary alternatives.

Safety and tolerability5.0/10

Controlled infusion avoids tablet-exposure uncertainty but not fluoroquinolone class risks: gastrointestinal, CNS, dysglycaemic, hypersensitivity, QT/tendon, cartilage, renal and interaction effects remain relevant. Exact-product veterinary safety margins and repeated-infusion data are absent, and rapid infusion can add venous or systemic risk.

Clinical practicality7.5/10

The 2 mg/ml ready infusion avoids compounding and permits accurate pump-controlled dosing in hospital. A 100 ml human vial can create substantial single-patient waste, requires aseptic handling and venous access, and must not be given as a rapid bolus.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use intravenous human ciprofloxacin empirically or for routine uncomplicated infection. Document a clinically important infection, collect diagnostic samples before treatment and show why lower-category and licensed veterinary options are unsuitable.
  • No approved veterinary susceptibility breakpoint exists for ciprofloxacin; human breakpoints must not be transferred to canine or feline isolates. A laboratory “susceptible” result alone does not validate a regimen—consult the laboratory or a veterinary microbiology/pharmacology specialist.
  • Never give as an undiluted or rapid intravenous bolus. Use a dedicated, controlled infusion and monitor the venous site and cardiovascular/neurologic status during administration; stop for collapse, severe reaction or marked infusion-site pain.
  • Cats are susceptible to potentially irreversible fluoroquinolone retinal degeneration. Avoid unnecessary use, calculate from exact weight, minimise peak and cumulative exposure, adjust for impaired elimination and stop urgently for mydriasis, visual change or disorientation.
  • Avoid systemic ciprofloxacin in growing dogs and cats unless no safer effective alternative exists. Fluoroquinolones can damage load-bearing cartilage in immature animals; record age, growth status and the exceptional justification.
  • Stop and reassess for seizure, tremor, marked agitation, confusion, ataxia or other CNS signs. Risk can rise with epilepsy, renal accumulation and concurrent NSAIDs or other medicines that lower the seizure threshold.
  • Ciprofloxacin inhibits CYP1A2. Concurrent tizanidine is contraindicated by the exact human labels; review theophylline/aminophylline, caffeine, ciclosporin, clozapine, ropinirole and vitamin-K antagonists and monitor or select another antimicrobial.
  • Review kidney function, hydration, electrolytes and urine output before and during treatment; adjust exposure in renal impairment. Maintain appropriate hydration while accounting for the infusion volume; crystalluria and renal injury are uncommon but important.
  • Monitor for vomiting, diarrhoea, anorexia, hypersensitivity, dysglycaemia, QT-related arrhythmia, lameness, tendon pain or rupture. Stop promptly for severe allergy, persistent gastrointestinal signs, new lameness or cardiovascular collapse.
  • The 2 mg/ml presentation is a ready infusion, not a concentrate. Inspect the solution and container, use aseptic single-patient handling, do not mix indiscriminately with other medicines and discard unused remainder according to the exact label and local policy.
Assessment sources
  1. Ciprinol 2 mg/ml regulator record2026
  2. Ciprinol infusion official SmPC2024
  3. ISCAID canine pyoderma 20252025
  4. ISCAID urinary guideline 20192019
  5. EMA AMEG fluoroquinolone category2019
  6. Canine intravenous ciprofloxacin PK1994
  7. Febrile-dog intravenous PK2009
  8. Feline oral ciprofloxacin PK2004
  9. Feline fluoroquinolone retinopathy2002
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Specialist-directed intravenous ciprofloxacin for a confirmed serious susceptible bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy
5.6/10
Weak evidence support
vetman assessment

Ciprinol

2 mg/ml, solution for infusion, 100 ml, human medicine
Assessed clinical scopeCat · Specialist-directed intravenous ciprofloxacin for a confirmed serious susceptible bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy · Intravenous
Care settingHospital treatment after diagnostic sampling, with controlled infusion, exact weight and renal assessment, interaction review, monitoring and culture-guided de-escalation.
vetman score 5.6/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-036072 · Verified on 16 Oct 2026 Off-label use

A weak feline hospital reserve. The ready IV solution is controllable and bypasses poor oral bioavailability, but limited outcome evidence, absent veterinary breakpoints and feline retinal risk require exceptional justification and favour a licensed alternative.

Regulatory and scientific credibility7.5/10

This exact human Ciprinol presentation has sourced active registrations in Georgia and EU/EEA and current exact product information, with no exact GB or US registration in the checked registers. Animal use is off-label and licensed veterinary fluoroquinolones are available.

Clinical efficacy5.0/10

A six-cat study directly describes rapid, wide intravenous disposition and suggests activity chiefly against selected Gram-negative organisms, so the route is more predictable than oral tablets. Evidence remains PK-based rather than a robust clinical-outcome programme; no approved veterinary ciprofloxacin breakpoint exists and licensed alternatives are better characterised.

Safety and tolerability3.5/10

Cats retain the class risk of potentially irreversible fluoroquinolone retinal degeneration, especially with high exposure, age or impaired elimination. Intravenous dosing makes peak exposure immediate; exact-product feline safety margins and repeated-infusion data are absent in addition to neurologic, cartilage, renal, interaction and infusion-related risks.

Clinical practicality7.0/10

The 2 mg/ml ready infusion is accurately measurable and avoids compounding, but a 100 ml human vial is oversized for most cats. Aseptic single-patient handling, venous access, pump control and discard of unused solution remain necessary.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use intravenous human ciprofloxacin empirically or for routine uncomplicated infection. Document a clinically important infection, collect diagnostic samples before treatment and show why lower-category and licensed veterinary options are unsuitable.
  • No approved veterinary susceptibility breakpoint exists for ciprofloxacin; human breakpoints must not be transferred to canine or feline isolates. A laboratory “susceptible” result alone does not validate a regimen—consult the laboratory or a veterinary microbiology/pharmacology specialist.
  • Never give as an undiluted or rapid intravenous bolus. Use a dedicated, controlled infusion and monitor the venous site and cardiovascular/neurologic status during administration; stop for collapse, severe reaction or marked infusion-site pain.
  • Cats are susceptible to potentially irreversible fluoroquinolone retinal degeneration. Avoid unnecessary use, calculate from exact weight, minimise peak and cumulative exposure, adjust for impaired elimination and stop urgently for mydriasis, visual change or disorientation.
  • Avoid systemic ciprofloxacin in growing dogs and cats unless no safer effective alternative exists. Fluoroquinolones can damage load-bearing cartilage in immature animals; record age, growth status and the exceptional justification.
  • Stop and reassess for seizure, tremor, marked agitation, confusion, ataxia or other CNS signs. Risk can rise with epilepsy, renal accumulation and concurrent NSAIDs or other medicines that lower the seizure threshold.
  • Ciprofloxacin inhibits CYP1A2. Concurrent tizanidine is contraindicated by the exact human labels; review theophylline/aminophylline, caffeine, ciclosporin, clozapine, ropinirole and vitamin-K antagonists and monitor or select another antimicrobial.
  • Review kidney function, hydration, electrolytes and urine output before and during treatment; adjust exposure in renal impairment. Maintain appropriate hydration while accounting for the infusion volume; crystalluria and renal injury are uncommon but important.
  • Monitor for vomiting, diarrhoea, anorexia, hypersensitivity, dysglycaemia, QT-related arrhythmia, lameness, tendon pain or rupture. Stop promptly for severe allergy, persistent gastrointestinal signs, new lameness or cardiovascular collapse.
  • The 2 mg/ml presentation is a ready infusion, not a concentrate. Inspect the solution and container, use aseptic single-patient handling, do not mix indiscriminately with other medicines and discard unused remainder according to the exact label and local policy.
Assessment sources
  1. Ciprinol 2 mg/ml regulator record2026
  2. Ciprinol infusion official SmPC2024
  3. ISCAID canine pyoderma 20252025
  4. ISCAID urinary guideline 20192019
  5. EMA AMEG fluoroquinolone category2019
  6. Canine intravenous ciprofloxacin PK1994
  7. Febrile-dog intravenous PK2009
  8. Feline oral ciprofloxacin PK2004
  9. Feline fluoroquinolone retinopathy2002
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Ciprofloxacin2 mg/ml
Formulation Type
Solution
Administration route
Intravenous
Manufacturer
Krka · Slovenia
Registration
Georgia Yes, human
In force until 03 Aug 2027
Human (Ministry of Health, RAMA)
In the register: ციპრინოლი 2 მგ/მლ, საინფუზიო ხსნარი, 100 მლ
№ რ-036072
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
10 mg/ml, Solution No label dose in the reference yet - Georgia Yes, human
In force until 13 Jul 2027
Human (Ministry of Health, RAMA)
In the register: ციპრინოლი 10 მგ/მლ, კონცენტრატი საინფუზიო ხსნარისთვის, 10 მლ ამპულა
№ რ-035845
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Ciprinol 10 mg/ml, Solution

concentrate for solution for infusion, 10 ml ampoule, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Specialist-directed intravenous ciprofloxacin for a confirmed serious susceptible bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy
5.9/10
Weak evidence support
vetman assessment

Ciprinol

10 mg/ml, concentrate for solution for infusion, 10 ml ampoule, human medicine
Assessed clinical scopeDog · Specialist-directed intravenous ciprofloxacin for a confirmed serious susceptible bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy · Intravenous
Care settingHospital treatment after diagnostic sampling, with controlled infusion, exact weight and renal assessment, interaction review, monitoring and culture-guided de-escalation.
vetman score 5.9/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-035845 · Verified on 16 Oct 2026 Off-label use

A weak specialist reserve. IV exposure can be predictable, but mandatory dilution, at least 50 ml final volume, preparation error potential, absent veterinary breakpoints and limited outcome evidence make the concentrate less practical than a ready licensed alternative.

Regulatory and scientific credibility7.5/10

This exact human Ciprinol presentation has sourced active registrations in Georgia and EU/EEA and current exact product information, with no exact GB or US registration in the checked registers. Animal use is off-label and licensed veterinary fluoroquinolones are available.

Clinical efficacy5.5/10

Intravenous delivery avoids the low and highly variable canine tablet absorption, and two small canine PK studies describe wide, linear disposition at 2.5-10 mg/kg and similar kinetics during induced fever. However, there is no robust veterinary clinical-outcome programme or approved ciprofloxacin breakpoint, while current guidelines reserve fluoroquinolones and favour licensed veterinary alternatives.

Safety and tolerability5.0/10

Controlled infusion avoids tablet-exposure uncertainty but not fluoroquinolone class risks: gastrointestinal, CNS, dysglycaemic, hypersensitivity, QT/tendon, cartilage, renal and interaction effects remain relevant. Exact-product veterinary safety margins and repeated-infusion data are absent, and rapid infusion can add venous or systemic risk.

Clinical practicality5.5/10

The 10 mg/ml concentrate is compact and measurable but must be diluted before use to at least 50 ml with a compatible fluid and prepared immediately. This adds calculation, compatibility, asepsis, fluid-volume and infusion-pump burden compared with a ready veterinary presentation.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use intravenous human ciprofloxacin empirically or for routine uncomplicated infection. Document a clinically important infection, collect diagnostic samples before treatment and show why lower-category and licensed veterinary options are unsuitable.
  • No approved veterinary susceptibility breakpoint exists for ciprofloxacin; human breakpoints must not be transferred to canine or feline isolates. A laboratory “susceptible” result alone does not validate a regimen—consult the laboratory or a veterinary microbiology/pharmacology specialist.
  • Never give as an undiluted or rapid intravenous bolus. Use a dedicated, controlled infusion and monitor the venous site and cardiovascular/neurologic status during administration; stop for collapse, severe reaction or marked infusion-site pain.
  • Cats are susceptible to potentially irreversible fluoroquinolone retinal degeneration. Avoid unnecessary use, calculate from exact weight, minimise peak and cumulative exposure, adjust for impaired elimination and stop urgently for mydriasis, visual change or disorientation.
  • Avoid systemic ciprofloxacin in growing dogs and cats unless no safer effective alternative exists. Fluoroquinolones can damage load-bearing cartilage in immature animals; record age, growth status and the exceptional justification.
  • Stop and reassess for seizure, tremor, marked agitation, confusion, ataxia or other CNS signs. Risk can rise with epilepsy, renal accumulation and concurrent NSAIDs or other medicines that lower the seizure threshold.
  • Ciprofloxacin inhibits CYP1A2. Concurrent tizanidine is contraindicated by the exact human labels; review theophylline/aminophylline, caffeine, ciclosporin, clozapine, ropinirole and vitamin-K antagonists and monitor or select another antimicrobial.
  • Review kidney function, hydration, electrolytes and urine output before and during treatment; adjust exposure in renal impairment. Maintain appropriate hydration while accounting for the infusion volume; crystalluria and renal injury are uncommon but important.
  • Monitor for vomiting, diarrhoea, anorexia, hypersensitivity, dysglycaemia, QT-related arrhythmia, lameness, tendon pain or rupture. Stop promptly for severe allergy, persistent gastrointestinal signs, new lameness or cardiovascular collapse.
  • The 10 mg/ml concentrate must be diluted before infusion to at least 50 ml with an exact-label compatible fluid and prepared immediately before use. Do not mix with solutions unstable at pH 3-4; administer incompatible medicines such as penicillins or heparin separately.
Assessment sources
  1. Ciprinol concentrate SmPC2025
  2. Ciprinol infusion official SmPC2024
  3. ISCAID canine pyoderma 20252025
  4. ISCAID urinary guideline 20192019
  5. EMA AMEG fluoroquinolone category2019
  6. Canine intravenous ciprofloxacin PK1994
  7. Febrile-dog intravenous PK2009
  8. Feline oral ciprofloxacin PK2004
  9. Feline fluoroquinolone retinopathy2002
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Specialist-directed intravenous ciprofloxacin for a confirmed serious susceptible bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy
5.1/10
Weak evidence support
vetman assessment

Ciprinol

10 mg/ml, concentrate for solution for infusion, 10 ml ampoule, human medicine
Assessed clinical scopeCat · Specialist-directed intravenous ciprofloxacin for a confirmed serious susceptible bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy · Intravenous
Care settingHospital treatment after diagnostic sampling, with controlled infusion, exact weight and renal assessment, interaction review, monitoring and culture-guided de-escalation.
vetman score 5.1/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-035845 · Verified on 16 Oct 2026 Off-label use

A weak and poorly matched feline presentation. Mandatory dilution to at least 50 ml compounds the class retinal risk, limited outcome evidence and absent veterinary breakpoints with a substantial fluid and preparation burden; prefer a licensed alternative.

Regulatory and scientific credibility7.5/10

This exact human Ciprinol presentation has sourced active registrations in Georgia and EU/EEA and current exact product information, with no exact GB or US registration in the checked registers. Animal use is off-label and licensed veterinary fluoroquinolones are available.

Clinical efficacy5.0/10

A six-cat study directly describes rapid, wide intravenous disposition and suggests activity chiefly against selected Gram-negative organisms, so the route is more predictable than oral tablets. Evidence remains PK-based rather than a robust clinical-outcome programme; no approved veterinary ciprofloxacin breakpoint exists and licensed alternatives are better characterised.

Safety and tolerability3.5/10

Cats retain the class risk of potentially irreversible fluoroquinolone retinal degeneration, especially with high exposure, age or impaired elimination. Intravenous dosing makes peak exposure immediate; exact-product feline safety margins and repeated-infusion data are absent in addition to neurologic, cartilage, renal, interaction and infusion-related risks.

Clinical practicality4.0/10

The 10 mg/ml concentrate must be diluted to at least 50 ml before use, a disproportionate fluid and preparation burden for most cats. Accurate withdrawal, compatible diluent, immediate preparation, asepsis, venous access and controlled infusion create a meaningful error and monitoring load.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use intravenous human ciprofloxacin empirically or for routine uncomplicated infection. Document a clinically important infection, collect diagnostic samples before treatment and show why lower-category and licensed veterinary options are unsuitable.
  • No approved veterinary susceptibility breakpoint exists for ciprofloxacin; human breakpoints must not be transferred to canine or feline isolates. A laboratory “susceptible” result alone does not validate a regimen—consult the laboratory or a veterinary microbiology/pharmacology specialist.
  • Never give as an undiluted or rapid intravenous bolus. Use a dedicated, controlled infusion and monitor the venous site and cardiovascular/neurologic status during administration; stop for collapse, severe reaction or marked infusion-site pain.
  • Cats are susceptible to potentially irreversible fluoroquinolone retinal degeneration. Avoid unnecessary use, calculate from exact weight, minimise peak and cumulative exposure, adjust for impaired elimination and stop urgently for mydriasis, visual change or disorientation.
  • Avoid systemic ciprofloxacin in growing dogs and cats unless no safer effective alternative exists. Fluoroquinolones can damage load-bearing cartilage in immature animals; record age, growth status and the exceptional justification.
  • Stop and reassess for seizure, tremor, marked agitation, confusion, ataxia or other CNS signs. Risk can rise with epilepsy, renal accumulation and concurrent NSAIDs or other medicines that lower the seizure threshold.
  • Ciprofloxacin inhibits CYP1A2. Concurrent tizanidine is contraindicated by the exact human labels; review theophylline/aminophylline, caffeine, ciclosporin, clozapine, ropinirole and vitamin-K antagonists and monitor or select another antimicrobial.
  • Review kidney function, hydration, electrolytes and urine output before and during treatment; adjust exposure in renal impairment. Maintain appropriate hydration while accounting for the infusion volume; crystalluria and renal injury are uncommon but important.
  • Monitor for vomiting, diarrhoea, anorexia, hypersensitivity, dysglycaemia, QT-related arrhythmia, lameness, tendon pain or rupture. Stop promptly for severe allergy, persistent gastrointestinal signs, new lameness or cardiovascular collapse.
  • The 10 mg/ml concentrate must be diluted before infusion to at least 50 ml with an exact-label compatible fluid and prepared immediately before use. Do not mix with solutions unstable at pH 3-4; administer incompatible medicines such as penicillins or heparin separately.
Assessment sources
  1. Ciprinol concentrate SmPC2025
  2. Ciprinol infusion official SmPC2024
  3. ISCAID canine pyoderma 20252025
  4. ISCAID urinary guideline 20192019
  5. EMA AMEG fluoroquinolone category2019
  6. Canine intravenous ciprofloxacin PK1994
  7. Febrile-dog intravenous PK2009
  8. Feline oral ciprofloxacin PK2004
  9. Feline fluoroquinolone retinopathy2002
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Ciprofloxacin10 mg/ml
Formulation Type
Solution
Administration route
Intravenous
Manufacturer
Krka · Slovenia
Registration
Georgia Yes, human
In force until 13 Jul 2027
Human (Ministry of Health, RAMA)
In the register: ციპრინოლი 10 მგ/მლ, კონცენტრატი საინფუზიო ხსნარისთვის, 10 მლ ამპულა
№ რ-035845
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
250 mg, Coated tablet No label dose in the reference yet - Georgia Yes, human
In force until 17 Mar 2028
Human (Ministry of Health, RAMA)
№ რ-037584
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Ciprinol 250 mg, Coated tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy
5.9/10
Weak evidence support
vetman assessment

Ciprinol

250 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy · By mouth
Care settingVeterinarian-directed treatment after sampling, with exact weight, renal and interaction review, early reassessment and culture-guided de-escalation.
vetman score 5.9/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-037584 · Verified on 15 Oct 2026 Off-label use

A weak reserve option rather than a routine veterinary fluoroquinolone. Even within this specialist-directed scope, oral tablet exposure is unpredictable and meaningful ciprofloxacin susceptibility interpretation and effective canine dosing are not established; prefer a licensed, better-characterised alternative whenever possible.

Regulatory and scientific credibility7.5/10

This exact human tablet family has sourced current registrations in Georgia and EU/EEA, current regulator-hosted product information and no exact GB or US registration in the checked registers. Animal use remains off-label and approved veterinary fluoroquinolones are available.

Clinical efficacy4.0/10

Ciprofloxacin has concentration-dependent activity against selected susceptible bacteria, but current ISCAID guidance excludes oral ciprofloxacin from canine pyoderma choices: tablet absorption is low and highly variable, veterinary susceptibility breakpoints are unavailable and an effective canine dose is not established. Urinary guidance also finds it difficult to justify over approved veterinary fluoroquinolones.

Safety and tolerability5.5/10

Gastrointestinal and CNS effects, dysglycaemia, hypersensitivity, QT/tendon risks, renal clearance and drug-chelation interactions are clinically relevant; immature animals are vulnerable to quinolone arthropathy. Correctly selected adult dogs can tolerate fluoroquinolones, but exact-product veterinary safety and dosing-margin data are absent.

Clinical practicality7.0/10

The scored 250 mg tablet can be halved to 125 mg and can match selected dog weights, but ciprofloxacin tablet dissolution itself is highly variable. Dose-unit flexibility does not solve uncertain exposure, and cation/feeding separation complicates reliable home use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use this human ciprofloxacin tablet empirically or for routine cystitis, superficial pyoderma, nonspecific diarrhoea or colonisation. Document infection, obtain diagnostic samples first and show that safer lower-category and licensed veterinary options are unsuitable.
  • No approved veterinary susceptibility breakpoint exists for ciprofloxacin and human breakpoints are inappropriate for canine isolates. A laboratory “susceptible” result alone cannot validate exposure from these tablets; consult the laboratory or a veterinary microbiology/pharmacology specialist.
  • Cats are susceptible to potentially irreversible fluoroquinolone retinal degeneration. Avoid unnecessary use; calculate from exact weight, reduce exposure with impaired renal elimination, avoid high peaks/prolonged courses and stop urgently for mydriasis, visual change or disorientation.
  • Avoid systemic ciprofloxacin in growing dogs and cats unless no safer effective alternative exists. Fluoroquinolones can damage load-bearing cartilage in immature animals; record age, growth status and the exceptional justification.
  • Stop and reassess for seizure, tremor, marked agitation, confusion, ataxia or other CNS signs. Risk can rise with epilepsy, renal accumulation and concurrent NSAIDs or other medicines that lower the seizure threshold.
  • Aluminium, magnesium, calcium, iron or zinc products, sucralfate and mineral supplements can markedly reduce oral absorption. Give ciprofloxacin at least 2 hours before or 4-6 hours after them; do not administer with dairy products or calcium-fortified drinks alone.
  • Ciprofloxacin inhibits CYP1A2. Concurrent tizanidine is contraindicated by the exact human labels; review theophylline/aminophylline, caffeine, ciclosporin, clozapine, ropinirole and vitamin-K antagonists and monitor or select another antimicrobial.
  • Review kidney function, hydration and urine output before and during treatment; adjust exposure in renal impairment and maintain hydration. Crystalluria and renal injury are uncommon but clinically important, especially with dehydration or excessive exposure.
  • Monitor for vomiting, diarrhoea, anorexia, hypersensitivity, dysglycaemia, QT-related arrhythmia, lameness, tendon pain or rupture. Stop promptly for severe allergy, persistent gastrointestinal signs, new lameness or cardiovascular collapse.
  • Use only the validated dose unit for the exact tablet. Ciprinol 250/500 and Cipro-Denk 500 can be divided into equal halves; the Cipro-Denk 750 score is only for easier swallowing and not equal dosing. Do not estimate smaller fractions or divide powder by eye.
Assessment sources
  1. Ciprinol official SmPC2026
  2. Ciprinol regulator register2026
  3. ISCAID canine pyoderma 20252025
  4. ISCAID urinary guideline 20192019
  5. EMA AMEG fluoroquinolone category2019
  6. Canine ciprofloxacin tablet PK2012
  7. Clinical canine ciprofloxacin PK2017
  8. Feline oral ciprofloxacin PK2004
  9. Feline fluoroquinolone retinopathy2002
  10. Veterinary oral formulation review2022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy
4.3/10
Weak evidence support
vetman assessment

Ciprinol

250 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy · By mouth
Care settingVeterinarian-directed treatment after sampling, with exact weight, renal and interaction review, early reassessment and culture-guided de-escalation.
vetman score 4.3/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-037584 · Verified on 15 Oct 2026 Off-label use

A poorly matched feline reserve presentation. Low oral bioavailability, no validated veterinary ciprofloxacin breakpoint, coarse 250-750 mg units and class retinal risk outweigh possible activity against selected Gram-negative isolates; use a better-characterised licensed alternative whenever possible.

Regulatory and scientific credibility7.5/10

This exact human tablet family has sourced current registrations in Georgia and EU/EEA, current regulator-hosted product information and no exact GB or US registration in the checked registers. Animal use remains off-label and approved veterinary fluoroquinolones are available.

Clinical efficacy3.5/10

A six-cat PK study found only 33% mean oral bioavailability at 10 mg/kg twice daily and no robust clinical-outcome programme supports these tablets. Potential Gram-negative activity does not overcome uncertain exposure, lack of veterinary ciprofloxacin breakpoints, superior licensed alternatives and the need to avoid empirical treatment of feline urinary signs.

Safety and tolerability4.0/10

Cats share the class risk of potentially irreversible fluoroquinolone retinal degeneration, especially with high exposure, prolonged treatment, age or impaired elimination. These coarse human tablets make peak exposure difficult to control; direct exact-product feline safety data are absent in addition to gastrointestinal, neurologic, cartilage and interaction risks.

Clinical practicality1.0/10

The validated unit for this exact 250 mg tablet is one half, still far above a typical measured feline dose. Unvalidated powder division cannot correct the mismatch; a licensed feline fluoroquinolone with an appropriate strength or suspension is substantially more controllable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use this human ciprofloxacin tablet empirically or for routine cystitis, superficial pyoderma, nonspecific diarrhoea or colonisation. Document infection, obtain diagnostic samples first and show that safer lower-category and licensed veterinary options are unsuitable.
  • No approved veterinary susceptibility breakpoint exists for ciprofloxacin and human breakpoints are inappropriate for canine isolates. A laboratory “susceptible” result alone cannot validate exposure from these tablets; consult the laboratory or a veterinary microbiology/pharmacology specialist.
  • Cats are susceptible to potentially irreversible fluoroquinolone retinal degeneration. Avoid unnecessary use; calculate from exact weight, reduce exposure with impaired renal elimination, avoid high peaks/prolonged courses and stop urgently for mydriasis, visual change or disorientation.
  • Avoid systemic ciprofloxacin in growing dogs and cats unless no safer effective alternative exists. Fluoroquinolones can damage load-bearing cartilage in immature animals; record age, growth status and the exceptional justification.
  • Stop and reassess for seizure, tremor, marked agitation, confusion, ataxia or other CNS signs. Risk can rise with epilepsy, renal accumulation and concurrent NSAIDs or other medicines that lower the seizure threshold.
  • Aluminium, magnesium, calcium, iron or zinc products, sucralfate and mineral supplements can markedly reduce oral absorption. Give ciprofloxacin at least 2 hours before or 4-6 hours after them; do not administer with dairy products or calcium-fortified drinks alone.
  • Ciprofloxacin inhibits CYP1A2. Concurrent tizanidine is contraindicated by the exact human labels; review theophylline/aminophylline, caffeine, ciclosporin, clozapine, ropinirole and vitamin-K antagonists and monitor or select another antimicrobial.
  • Review kidney function, hydration and urine output before and during treatment; adjust exposure in renal impairment and maintain hydration. Crystalluria and renal injury are uncommon but clinically important, especially with dehydration or excessive exposure.
  • Monitor for vomiting, diarrhoea, anorexia, hypersensitivity, dysglycaemia, QT-related arrhythmia, lameness, tendon pain or rupture. Stop promptly for severe allergy, persistent gastrointestinal signs, new lameness or cardiovascular collapse.
  • Use only the validated dose unit for the exact tablet. Ciprinol 250/500 and Cipro-Denk 500 can be divided into equal halves; the Cipro-Denk 750 score is only for easier swallowing and not equal dosing. Do not estimate smaller fractions or divide powder by eye.
Assessment sources
  1. Ciprinol official SmPC2026
  2. Ciprinol regulator register2026
  3. ISCAID canine pyoderma 20252025
  4. ISCAID urinary guideline 20192019
  5. EMA AMEG fluoroquinolone category2019
  6. Canine ciprofloxacin tablet PK2012
  7. Clinical canine ciprofloxacin PK2017
  8. Feline oral ciprofloxacin PK2004
  9. Feline fluoroquinolone retinopathy2002
  10. Veterinary oral formulation review2022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Ciprofloxacin250 mg
Formulation Type
Coated tablet
Administration route
By mouth
Manufacturer
Krka · Slovenia
Registration
Georgia Yes, human
In force until 17 Mar 2028
Human (Ministry of Health, RAMA)
№ რ-037584
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
500 mg, Coated tablet No label dose in the reference yet - Georgia Yes, human
In force until 17 Mar 2028
Human (Ministry of Health, RAMA)
№ რ-037585
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Ciprinol 500 mg, Coated tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy
5.8/10
Weak evidence support
vetman assessment

Ciprinol

500 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy · By mouth
Care settingVeterinarian-directed treatment after sampling, with exact weight, renal and interaction review, early reassessment and culture-guided de-escalation.
vetman score 5.8/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-037585 · Verified on 15 Oct 2026 Off-label use

A weak reserve option rather than a routine veterinary fluoroquinolone. Even within this specialist-directed scope, oral tablet exposure is unpredictable and meaningful ciprofloxacin susceptibility interpretation and effective canine dosing are not established; prefer a licensed, better-characterised alternative whenever possible.

Regulatory and scientific credibility7.5/10

This exact human tablet family has sourced current registrations in Georgia and EU/EEA, current regulator-hosted product information and no exact GB or US registration in the checked registers. Animal use remains off-label and approved veterinary fluoroquinolones are available.

Clinical efficacy4.0/10

Ciprofloxacin has concentration-dependent activity against selected susceptible bacteria, but current ISCAID guidance excludes oral ciprofloxacin from canine pyoderma choices: tablet absorption is low and highly variable, veterinary susceptibility breakpoints are unavailable and an effective canine dose is not established. Urinary guidance also finds it difficult to justify over approved veterinary fluoroquinolones.

Safety and tolerability5.5/10

Gastrointestinal and CNS effects, dysglycaemia, hypersensitivity, QT/tendon risks, renal clearance and drug-chelation interactions are clinically relevant; immature animals are vulnerable to quinolone arthropathy. Correctly selected adult dogs can tolerate fluoroquinolones, but exact-product veterinary safety and dosing-margin data are absent.

Clinical practicality6.5/10

The scored 500 mg tablet can be halved to 250 mg and is workable for selected medium-to-large dogs, but remains coarse for small dogs and renal adjustment. Variable tablet dissolution and cation/feeding separation reduce reliability despite simple storage.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use this human ciprofloxacin tablet empirically or for routine cystitis, superficial pyoderma, nonspecific diarrhoea or colonisation. Document infection, obtain diagnostic samples first and show that safer lower-category and licensed veterinary options are unsuitable.
  • No approved veterinary susceptibility breakpoint exists for ciprofloxacin and human breakpoints are inappropriate for canine isolates. A laboratory “susceptible” result alone cannot validate exposure from these tablets; consult the laboratory or a veterinary microbiology/pharmacology specialist.
  • Cats are susceptible to potentially irreversible fluoroquinolone retinal degeneration. Avoid unnecessary use; calculate from exact weight, reduce exposure with impaired renal elimination, avoid high peaks/prolonged courses and stop urgently for mydriasis, visual change or disorientation.
  • Avoid systemic ciprofloxacin in growing dogs and cats unless no safer effective alternative exists. Fluoroquinolones can damage load-bearing cartilage in immature animals; record age, growth status and the exceptional justification.
  • Stop and reassess for seizure, tremor, marked agitation, confusion, ataxia or other CNS signs. Risk can rise with epilepsy, renal accumulation and concurrent NSAIDs or other medicines that lower the seizure threshold.
  • Aluminium, magnesium, calcium, iron or zinc products, sucralfate and mineral supplements can markedly reduce oral absorption. Give ciprofloxacin at least 2 hours before or 4-6 hours after them; do not administer with dairy products or calcium-fortified drinks alone.
  • Ciprofloxacin inhibits CYP1A2. Concurrent tizanidine is contraindicated by the exact human labels; review theophylline/aminophylline, caffeine, ciclosporin, clozapine, ropinirole and vitamin-K antagonists and monitor or select another antimicrobial.
  • Review kidney function, hydration and urine output before and during treatment; adjust exposure in renal impairment and maintain hydration. Crystalluria and renal injury are uncommon but clinically important, especially with dehydration or excessive exposure.
  • Monitor for vomiting, diarrhoea, anorexia, hypersensitivity, dysglycaemia, QT-related arrhythmia, lameness, tendon pain or rupture. Stop promptly for severe allergy, persistent gastrointestinal signs, new lameness or cardiovascular collapse.
  • Use only the validated dose unit for the exact tablet. Ciprinol 250/500 and Cipro-Denk 500 can be divided into equal halves; the Cipro-Denk 750 score is only for easier swallowing and not equal dosing. Do not estimate smaller fractions or divide powder by eye.
Assessment sources
  1. Ciprinol official SmPC2026
  2. Ciprinol regulator register2026
  3. ISCAID canine pyoderma 20252025
  4. ISCAID urinary guideline 20192019
  5. EMA AMEG fluoroquinolone category2019
  6. Canine ciprofloxacin tablet PK2012
  7. Clinical canine ciprofloxacin PK2017
  8. Feline oral ciprofloxacin PK2004
  9. Feline fluoroquinolone retinopathy2002
  10. Veterinary oral formulation review2022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy
4.3/10
Weak evidence support
vetman assessment

Ciprinol

500 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy · By mouth
Care settingVeterinarian-directed treatment after sampling, with exact weight, renal and interaction review, early reassessment and culture-guided de-escalation.
vetman score 4.3/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-037585 · Verified on 15 Oct 2026 Off-label use

A poorly matched feline reserve presentation. Low oral bioavailability, no validated veterinary ciprofloxacin breakpoint, coarse 250-750 mg units and class retinal risk outweigh possible activity against selected Gram-negative isolates; use a better-characterised licensed alternative whenever possible.

Regulatory and scientific credibility7.5/10

This exact human tablet family has sourced current registrations in Georgia and EU/EEA, current regulator-hosted product information and no exact GB or US registration in the checked registers. Animal use remains off-label and approved veterinary fluoroquinolones are available.

Clinical efficacy3.5/10

A six-cat PK study found only 33% mean oral bioavailability at 10 mg/kg twice daily and no robust clinical-outcome programme supports these tablets. Potential Gram-negative activity does not overcome uncertain exposure, lack of veterinary ciprofloxacin breakpoints, superior licensed alternatives and the need to avoid empirical treatment of feline urinary signs.

Safety and tolerability4.0/10

Cats share the class risk of potentially irreversible fluoroquinolone retinal degeneration, especially with high exposure, prolonged treatment, age or impaired elimination. These coarse human tablets make peak exposure difficult to control; direct exact-product feline safety data are absent in addition to gastrointestinal, neurologic, cartilage and interaction risks.

Clinical practicality0.5/10

The validated unit for this exact 500 mg tablet is one half, still far above a typical measured feline dose. Unvalidated powder division cannot correct the mismatch; a licensed feline fluoroquinolone with an appropriate strength or suspension is substantially more controllable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use this human ciprofloxacin tablet empirically or for routine cystitis, superficial pyoderma, nonspecific diarrhoea or colonisation. Document infection, obtain diagnostic samples first and show that safer lower-category and licensed veterinary options are unsuitable.
  • No approved veterinary susceptibility breakpoint exists for ciprofloxacin and human breakpoints are inappropriate for canine isolates. A laboratory “susceptible” result alone cannot validate exposure from these tablets; consult the laboratory or a veterinary microbiology/pharmacology specialist.
  • Cats are susceptible to potentially irreversible fluoroquinolone retinal degeneration. Avoid unnecessary use; calculate from exact weight, reduce exposure with impaired renal elimination, avoid high peaks/prolonged courses and stop urgently for mydriasis, visual change or disorientation.
  • Avoid systemic ciprofloxacin in growing dogs and cats unless no safer effective alternative exists. Fluoroquinolones can damage load-bearing cartilage in immature animals; record age, growth status and the exceptional justification.
  • Stop and reassess for seizure, tremor, marked agitation, confusion, ataxia or other CNS signs. Risk can rise with epilepsy, renal accumulation and concurrent NSAIDs or other medicines that lower the seizure threshold.
  • Aluminium, magnesium, calcium, iron or zinc products, sucralfate and mineral supplements can markedly reduce oral absorption. Give ciprofloxacin at least 2 hours before or 4-6 hours after them; do not administer with dairy products or calcium-fortified drinks alone.
  • Ciprofloxacin inhibits CYP1A2. Concurrent tizanidine is contraindicated by the exact human labels; review theophylline/aminophylline, caffeine, ciclosporin, clozapine, ropinirole and vitamin-K antagonists and monitor or select another antimicrobial.
  • Review kidney function, hydration and urine output before and during treatment; adjust exposure in renal impairment and maintain hydration. Crystalluria and renal injury are uncommon but clinically important, especially with dehydration or excessive exposure.
  • Monitor for vomiting, diarrhoea, anorexia, hypersensitivity, dysglycaemia, QT-related arrhythmia, lameness, tendon pain or rupture. Stop promptly for severe allergy, persistent gastrointestinal signs, new lameness or cardiovascular collapse.
  • Use only the validated dose unit for the exact tablet. Ciprinol 250/500 and Cipro-Denk 500 can be divided into equal halves; the Cipro-Denk 750 score is only for easier swallowing and not equal dosing. Do not estimate smaller fractions or divide powder by eye.
Assessment sources
  1. Ciprinol official SmPC2026
  2. Ciprinol regulator register2026
  3. ISCAID canine pyoderma 20252025
  4. ISCAID urinary guideline 20192019
  5. EMA AMEG fluoroquinolone category2019
  6. Canine ciprofloxacin tablet PK2012
  7. Clinical canine ciprofloxacin PK2017
  8. Feline oral ciprofloxacin PK2004
  9. Feline fluoroquinolone retinopathy2002
  10. Veterinary oral formulation review2022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Ciprofloxacin500 mg
Formulation Type
Coated tablet
Administration route
By mouth
Manufacturer
Krka · Slovenia
Registration
Georgia Yes, human
In force until 17 Mar 2028
Human (Ministry of Health, RAMA)
№ რ-037585
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Ciprofloxacin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
25–50 mg/kg
off-label
 Dog Bacterial Infection
adults
 By mouth once daily
MSD Vet Manual 2026
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Quinolones, Including Fluoroquinolones, for Use in Animals
MSD/Merck Veterinary Manual, 2026

Known Contraindications

  • Critical
    Do not use ciprofloxacin in patients with known hypersensitivity to ciprofloxacin or another fluoroquinolone.
  • Warning
    Both ciprofloxacin and moxifloxacin have been associated with potentially fatal antimicrobial-induced colitis.
    Sources: MSD Vet Manual
  • Warning
    Avoid excessive or prolonged quinolone use in immature animals because cartilage erosion and permanent lameness have occurred in growing dogs and foals.
    Sources: MSD Vet Manual
  • Warning (Cat)
    Not well absorbed in cats
    Sources: MSD Vet Manual

Known Drug Interactions

  • Major warning Ciprofloxacin + Aminophylline
    Serious and fatal reactions have been reported in patients receiving concurrent administration of CIPRO and theophylline. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)
    Recommendation: Avoid concurrent use when possible. If the combination is unavoidable, monitor serum theophylline and reduce the aminophylline dose as needed. Watch for nausea, vomiting, tremor, excitation, tachycardia, and seizures.
    Sources: FDA
  • Major warning Theophylline + Ciprofloxacin
    Serious and fatal reactions have been reported in patients receiving concurrent administration of CIPRO and theophylline. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)
    Recommendation: Avoid concurrent use when possible. If the combination is unavoidable, monitor serum theophylline and reduce its dose as needed. Watch for nausea, vomiting, tremor, excitation, tachycardia, and seizures.
    Sources: FDA

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗